Showing results (1031-1040 of 1,547) with videos related to
Sort By:
Pageof 155
Neuro-Oncology|December 10, 2023
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effortJoshua A Budhu, Ugonma N Chukwueke, Sadhana Jackson, et al.Neuro-Oncology|December 18, 2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)Timothy F Cloughesy, Andrew Brenner, John F de Groot, et al.The Lancet. Oncology|March 7, 2018
Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiativeLinda Dirven, Terri S Armstrong, Jaishri O Blakeley, et al.Cancer|December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastomaDavid A Reardon, Andrew B Lassman, David Schiff, et al.NPJ Breast Cancer|March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumabEmanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.Neuro-Oncology|May 6, 2020
Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV GliomasDenise Bernhardt, Wolfgang Wick, Stephanie E Weiss, et al.Clinical Pharmacology and Therapeutics|March 19, 2014
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignanciesS Karovic, Y Wen, T G Karrison, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase II study of protracted daily temozolomide for low-grade gliomas in adultsSantosh Kesari, David Schiff, Jan Drappatz, et al.Journal of Clinical Pathology|November 2, 2022
<i>KIT</i> genetic alterations in breast cancerMahsa Vahdatinia, Fatemeh Derakhshan, Arnaud Da Cruz Paula, et al.Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.Pageof 155